GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (STU:MMQ) » Definitions » Shares Outstanding (EOP)

Mind Medicine (STU:MMQ) Shares Outstanding (EOP) : 75.10 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Mind Medicine Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Mind Medicine's shares outstanding for the quarter that ended in Dec. 2024 was 75.10 Mil.

Mind Medicine's quarterly shares outstanding declined from Sep. 2024 (81.59 Mil) to Dec. 2024 (75.10 Mil). It means Mind Medicine bought back shares from Sep. 2024 to Dec. 2024 .

Mind Medicine's annual shares outstanding increased from Dec. 2023 (41.10 Mil) to Dec. 2024 (75.10 Mil). It means Mind Medicine issued new shares from Dec. 2023 to Dec. 2024 .


Mind Medicine Shares Outstanding (EOP) Historical Data

The historical data trend for Mind Medicine's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine Shares Outstanding (EOP) Chart

Mind Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Shares Outstanding (EOP)
20.45 28.10 37.98 41.10 75.10

Mind Medicine Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.10 71.16 72.08 81.59 75.10

Competitive Comparison of Mind Medicine's Shares Outstanding (EOP)

For the Biotechnology subindustry, Mind Medicine's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mind Medicine's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mind Medicine's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Mind Medicine's Shares Outstanding (EOP) falls into.


;
;

Mind Medicine Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Mind Medicine  (STU:MMQ) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Mind Medicine Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Mind Medicine's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Mind Medicine Business Description

Traded in Other Exchanges
Address
One World Trade Center, Suite 8500, New York, NY, USA, 10007
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Mind Medicine Headlines

No Headlines